Leonardo L G Ferreira

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5720463/publications.pdf

Version: 2024-02-01

57 papers	2,401 citations	471509 17 h-index	223800 46 g-index
57 all docs	57 docs citations	57 times ranked	3287 citing authors

#	Article	IF	Citations
1	Approaches to advance drug discovery for neglected tropical diseases. Drug Discovery Today, 2022, 27, 2278-2287.	6.4	35
2	Novel trypanocidal thiophen-chalcone cruzain inhibitors: structure- and ligand-based studies. Future Medicinal Chemistry, 2022, 14, 795-808.	2.3	6
3	Liquid Fungal Cocultivation as a Strategy to Access Bioactive Metabolites. Planta Medica, 2021, 87, 187-195.	1.3	1
4	Antileishmanial macrolides from ant-associated Streptomyces sp. ISID311. Bioorganic and Medicinal Chemistry, 2021, 32, 116016.	3.0	14
5	2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. PLoS Neglected Tropical Diseases, 2021, 15, e0009196.	3.0	8
6	Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors. Biomolecules, 2021, 11, 579.	4.0	8
7	2',6'-dihydroxy-4'-methoxy Dihydrochalcone Improves the Cognitive Impairment of Alzheimer's Disease: A Structure-activity Relationship Study. Current Topics in Medicinal Chemistry, 2021, 21, 1167-1185.	2.1	3
8	Diaminomaleonitrile derivatives as new potential antichagasic compounds: a study of structureâ€“activity relationships. Future Medicinal Chemistry, 2021, 13, 2167-2183.	2.3	3
9	Antioxidant Activity, Molecular Docking, Quantum Studies and In Vivo Antinociceptive Activity of Sulfonamides Derived From Carvacrol. Frontiers in Pharmacology, 2021, 12, 788850.	3.5	3
10	Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics. Frontiers in Pharmacology, 2021, 12, 774069.	3.5	6
11	Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach. Journal of Chemical Information and Modeling, 2020, 60, 1028-1041.	5.4	32
12	Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents. RSC Medicinal Chemistry, 2020, 11, 1267-1274.	3.9	5
13	H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies. Parasites and Vectors, 2020, 13, 278.	2.5	28
14	Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors. Molecules, 2020, 25, 264.	3.8	7
15	Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids. European Journal of Medicinal Chemistry, 2020, 201, 112418.	5.5	10
16	Meliponamycins: Antimicrobials from Stingless Bee-Associated Streptomyces sp.. Journal of Natural Products, 2020, 83, 610-616.	3.0	29
17	Medicamentos e tratamentos para a Covid-19. Estudos Avancados, 2020, 34, 7-27.	0.5	15
18	Antioxidant and Antibacterial Activity of Sulfonamides Derived from Carvacrol: A Structure-Activity Relationship Study. Current Topics in Medicinal Chemistry, 2020, 20, 173-181.	2.1	5

#	Article	IF	Citations
19	COVID-19: Small-Molecule Clinical Trials Landscape. Current Topics in Medicinal Chemistry, 2020, 20, 1577-1580.	2.1	8
20	Molecular Docking and Quantum Studies of Lawsone Dimers Derivatives: New Investigation of Antioxidant Behavior and Antifungal Activity. Current Topics in Medicinal Chemistry, 2020, 20, 182-191.	2.1	1
21	World Chagas Disease Day and the New Road Map for Neglected Tropical Diseases. Current Topics in Medicinal Chemistry, 2020, 20, 1518-1520.	2.1	6
22	Cancer Estimates in Brazil Reveal Progress for the Most Lethal Malignancies. Current Topics in Medicinal Chemistry, 2020, 20, 1962-1966.	2.1	1
23	Antifungal compounds from Streptomyces associated with attine ants also inhibit Leishmania donovani. PLoS Neglected Tropical Diseases, 2019, 13, e0007643.	3.0	39
24	Drugs and vaccines in the 21st century for neglected diseases. Lancet Infectious Diseases, The, 2019, 19, 125-127.	9.1	28
25	Quantitative Structureâ€“Activity Relationships for Structurally Diverse Chemotypes Having Anti-Trypanosoma cruzi Activity. International Journal of Molecular Sciences, 2019, 20, 2801.	4.1	13
26	Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis. EBioMedicine, 2019, 43, 370-379.	6.1	47
27	From chemoinformatics to deep learning: an open road to drug discovery. Future Medicinal Chemistry, 2019, 11, 371-374.	2.3	10
28	ADMET modeling approaches in drug discovery. Drug Discovery Today, 2019, 24, 1157-1165.	6.4	333
29	Synthesis of a novel brominated vinylic fatty acid with antileishmanial activity that effectively inhibits the Leishmania topoisomerase IB enzyme mediated by halogen bond formation. Pure and Applied Chemistry, 2019, 91, 1405-1416.	1.9	3
30	Structure-Based and Molecular Modeling Studies for the Discovery of Cyclic Imides as Reversible Cruzain Inhibitors With Potent Anti-Trypanosoma cruzi Activity. Frontiers in Chemistry, 2019, 7, 798.	3.6	24
31	Practices in Molecular Docking and Structure-Based Virtual Screening. Methods in Molecular Biology, 2018, 1762, 31-50.	0.9	34
32	Chemoinformatics Strategies for Leishmaniasis Drug Discovery. Frontiers in Pharmacology, 2018, 9, 1278.	3.5	16
33	Editorial: Chemoinformatics Approaches to Structure- and Ligand-Based Drug Design. Frontiers in Pharmacology, 2018, 9, 1416.	3.5	13
34	From Medicinal Chemistry to Human Health: Current Approaches to Drug Discovery for Cancer and Neglected Tropical Diseases. Anais Da Academia Brasileira De Ciencias, 2018, 90, 645-661.	0.8	15
35	Editorial: Drug Discovery for Neglected Diseases. Current Topics in Medicinal Chemistry, 2018, 18, 313-314.	2.1	0
36	Recent Advances and Perspectives in Cancer Drug Design. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1233-1250.	0.8	38

#	Article	IF	Citations
37	Structure-Based Virtual Screening and Biochemical Evaluation for the Identification of Novel Trypanosoma brucei Aldolase Inhibitors. Current Topics in Medicinal Chemistry, 2018, 18, 397-405.	2.1	5
38	Molecular modeling and structureâ€“activity relationships for a series of benzimidazole derivatives as cruzain inhibitors. Future Medicinal Chemistry, 2017, 9, 641-657.	2.3	18
39	Targeting cysteine proteases in trypanosomatid disease drug discovery. , 2017, 180, 49-61.		49
40	2D and 3D QSAR Studies on a Series of Antichagasic Fenarimol Derivatives. International Journal of Quantitative Structure-Property Relationships, 2017, 2, 44-63.	0.5	2
41	From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery. Current Topics in Medicinal Chemistry, 2017, 17, 2260-2270.	2.1	10
42	2D and 3D QSAR Studies on a Series of Antichagasic Fenarimol Derivatives. , 2017, , 956-977.		0
43	Discovery of Novel Antischistosomal Agents by Molecular Modeling Approaches. Trends in Parasitology, 2016, 32, 874-886.	3.3	45
44	Protein-protein interaction inhibitors: advances in anticancer drug design. Expert Opinion on Drug Discovery, 2016, 11, 957-968.	5.0	25
45	Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. Drug Discovery Today, 2016, 21, 1699-1710.	6.4	65
46	Advances and Progress in Chagas Disease Drug Discovery. Current Topics in Medicinal Chemistry, 2016, 16, 2290-2302.	2.1	17
47	Molecular Docking and Structure-Based Drug Design Strategies. Molecules, 2015, 20, 13384-13421.	3.8	1,255
48	Target-based molecular modeling strategies for schistosomiasis drug discovery. Future Medicinal Chemistry, 2015, 7, 753-764.	2.3	27
49	Fragment-Based QSAR and Structural Analysis of a Series of Hydroxyethylamine Derivatives as HIV-1 Protease Inhibitors. Combinatorial Chemistry and High Throughput Screening, 2015, 18, 464-475.	1.1	3
50	Medicinal Chemistry Approaches to Neglected Diseases Drug Discovery. Journal of Modern Medicinal Chemistry, 2014, 2, 20-31.	0.8	3
51	Inhibitors of Trypanosoma brucei trypanothione reductase: comparative molecular field analysis modeling and structural basis for selective inhibition. Future Medicinal Chemistry, 2013, 5, 1753-1762.	2.3	8
52	Structure-Based Drug Design Studies on a Series of Aldolase Inhibitors. Journal of the Brazilian Chemical Society, 2013, 24, 201-211.	0.6	2
53	Structure- and Ligand-Based Structure-Activity Relationships for a Series of Inhibitors of Aldolase. Current Computer-Aided Drug Design, 2012, 8, 309-316.	1.2	2
54	Comparative Molecular Field Analysis of a Series of Inhibitors of HIV-1 Protease. Medicinal Chemistry, 2011, 7, 71-79.	1.5	4

#	Article	IF	Citations
55	Hologram Quantitative Structure-Activity Relationships for a Class of Inhibitors of HIV-1 Protease. Letters in Drug Design and Discovery, 2007, 4, 356-364.	0.7	4
56	Susceptibility of Angiostrongylus cantonensis Larvae to Anthelmintic Drugs. Frontiers in Pharmacology, 0, 13, .	3.5	10
57	Editorial: Chemoinformatics Approaches to Structure- and Ligand-Based Drug Design, Volume II. Frontiers in Pharmacology, 0, 13, .	3.5	0